DDInter93 DDInter1729
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Anagrelide {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Sulindac
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Caffeine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Nifedipine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Sulindac
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Caffeine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Sulindac
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Nifedipine {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Sulindac
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Citalopram
Citalopram {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Anagrelide (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sulindac (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caffeine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sulindac (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caffeine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Sulindac (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sulindac (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)